Brief: Cyxone Receives Pre-IND Response From FDA

Cyxone AB

12/07/2022 08:10

July 12 (Reuters) - Cyxone AB  CYXO.ST :
    * RECEIVES PRE-IND RESPONSE FROM THE US FDA REGARDING RA
STUDY
    * RESPONSE FROM FDA FACILITATES FOR CYXONE TO CONTINUE
PLANNING
PHASE 2B STUDY WITH RABEXIMOD IN RA

Source text for Eikon:  ID:nWkr5s0bvk 
Further company coverage:  CYXO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))